Is there a role for dehydroepiandrosterone replacement in the intensive care population?
Dhatariya
Ketan K
KK
Endocrine Research Unit, Mayo Clinic, Rochester, Minn., USA. dhatariya.ketan@mayo.edu
D000276:Adjuvants, Immunologic / Q000494:pharmacology / Q000627:therapeutic use*; D000309:Adrenal Insufficiency / Q000188:drug therapy / Q000453:epidemiology / Q000209:etiology; D000367:Age Factors; D003422:Critical Care / Q000379:methods*; D016638:Critical Illness / Q000628:therapy*; D003687:Dehydroepiandrosterone / Q000172:deficiency* / Q000494:pharmacology / Q000627:therapeutic use*; D019317:Evidence-Based Medicine; D020249:Hormone Replacement Therapy / Q000379:methods / Q000592:standards; D006801:Humans; D016019:Survival Analysis; D016896:Treatment Outcome
D000276:Adjuvants, Immunologic; D003687:Dehydroepiandrosterone